482 related articles for article (PubMed ID: 14751424)
21. Risperidone-related weight gain: genetic and nongenetic predictors.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
[TBL] [Abstract][Full Text] [Related]
22. [Perospirone therapy in elderly patients with schizophrenia].
Masui T; Honma H; Kondo C; Osawa T; Iwasaki S; Matsubara S
Seishin Shinkeigaku Zasshi; 2003; 105(10):1247-53. PubMed ID: 14679781
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
[TBL] [Abstract][Full Text] [Related]
24. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
25. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
[TBL] [Abstract][Full Text] [Related]
27. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
28. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
29. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
Lim HK; Kim JJ; Pae CU; Lee CU; Lee C; Paik IH
Neuropsychobiology; 2010; 62(2):81-6. PubMed ID: 20523078
[TBL] [Abstract][Full Text] [Related]
30. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone.
Kim JH; Kim MJ
Clin Neuropharmacol; 2009; 32(5):250-3. PubMed ID: 19620847
[TBL] [Abstract][Full Text] [Related]
31. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
Rémillard S; Pourcher E; Cohen H
J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537
[TBL] [Abstract][Full Text] [Related]
32. Negative symptoms in schizophrenia: assessment of the effect of risperidone.
Schooler NR
J Clin Psychiatry; 1994 May; 55 Suppl():22-8. PubMed ID: 7520905
[TBL] [Abstract][Full Text] [Related]
33. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
Himei A; Okamura T
Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore.
Chong SA; Yap HL; Low BL; Choo CH; Chan AO; Wong KE; Mahendran R; Chee KT
Singapore Med J; 1999 Jan; 40(1):41-3. PubMed ID: 10361485
[TBL] [Abstract][Full Text] [Related]
36. Risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia.
Kusumi I; Honda M; Ito K; Uemura K; Kumazawa Y; Ishikane T; Niide Y; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):537-40. PubMed ID: 21168464
[TBL] [Abstract][Full Text] [Related]
37. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
[TBL] [Abstract][Full Text] [Related]
38. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
39. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
Fang M; Chen H; Li LH; Wu R; Li Y; Liu L; Ye M; Huang J; Zhu S; Wang G; Zhang Q; Zheng H; Zhang L; Wang B; Zhou J; Zhao JP
Int Clin Psychopharmacol; 2012 Mar; 27(2):107-13. PubMed ID: 22233697
[TBL] [Abstract][Full Text] [Related]
40. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
Glick ID; Lemmens P; Vester-Blokland E
Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
